 - HBV fields first c ore i nhibitor combination study to assess off-treatment response has not achieve d a meaningful rate of sustained virologic response - - Vebicorvir Phase 3 registrational program remain s on track to i nitiate in H1 2021 for c hronic s uppressive t herapy - - Assembly Bio to host conference call today at 5:00 p . m . ET - 